These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 7734355)

  • 1. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.
    Westin J; Rödjer S; Turesson I; Cortelezzi A; Hjorth M; Zador G
    Br J Haematol; 1995 Mar; 89(3):561-8. PubMed ID: 7734355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.
    Westin J
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):37-40. PubMed ID: 1948128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
    Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
    Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.
    Westin J; Cortelezzi A; Hjorth M; Rödjer S; Turesson I; Zador G
    Eur J Cancer; 1991; 27 Suppl 4():S45-8. PubMed ID: 1799477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
    Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
    Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
    Cooper MR; Dear K; McIntyre OR; Ozer H; Ellerton J; Canellos G; Bernhardt B; Duggan D; Faragher D; Schiffer C
    J Clin Oncol; 1993 Jan; 11(1):155-60. PubMed ID: 8418228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
    Bladé J; San Miguel JF; Escudero ML; Fontanillas M; Besalduch J; Gardella S; Arias J; García-Conde J; Carnero M; Marti JM; Rozman C; Estapé J; Montserrat E
    Leukemia; 1998 Jul; 12(7):1144-8. PubMed ID: 9665202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
    Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
    Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.
    Wisløff F; Hjorth M; Kaasa S; Westin J
    Br J Haematol; 1996 Aug; 94(2):324-32. PubMed ID: 8759893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
    Zervas K; Pouli A; Perifanis V; Papanastasiou K; Chatziyianni M; Mitsouli C; Maniatis A
    Eur J Haematol; 1996 Aug; 57(2):142-8. PubMed ID: 8856091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.
    Ludwig H; Cohen AM; Polliack A; Huber H; Nachbaur D; Senn HJ; Morant R; Eckhardt S; Günczler P; Seewann HL
    Ann Oncol; 1995 May; 6(5):467-76. PubMed ID: 7669712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma.
    Montuoro A; De Rosa L; De Blasio A; Pacilli L; Petti N; De Laurenzi A
    Br J Haematol; 1990 Nov; 76(3):365-8. PubMed ID: 2261347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.
    Osterborg A; Björkholm M; Björeman M; Brenning G; Carlson K; Celsing F; Gahrton G; Grimfors G; Gyllenhammar H; Hast R
    Blood; 1993 Mar; 81(6):1428-34. PubMed ID: 8453092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.
    Mandelli F; Avvisati G; Amadori S; Boccadoro M; Gernone A; Lauta VM; Marmont F; Petrucci MT; Tribalto M; Vegna ML
    N Engl J Med; 1990 May; 322(20):1430-4. PubMed ID: 2184356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC Working Party on Leukaemia in Adults.
    Drayson MT; Chapman CE; Dunn JA; Olujohungbe AB; Maclennan IC
    Br J Haematol; 1998 Apr; 101(1):195-202. PubMed ID: 9576201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
    Gola A; Usnarska-Zubkiewicz L; Wołowiec D; Urbaniak-Kujda D; Kotlarek-Haus S
    Pol Arch Med Wewn; 1993 Aug; 90(2):134-41. PubMed ID: 8247946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.